Inositol for women: what indicators were studied in studies

The phrase “inositol for women” sounds as though it refers to a single specific effect. In fact, studies of inositol involving women vary widely: some measured glucose and insulin, others examined lipids and blood pressure, while still others looked at body weight, hormones, menstrual cycle length, or particular laboratory markers.

The right question, therefore, is not “what does inositol do for women?” but“what exactly was tested in a particular study, in which women, and which measure was used to assess the outcome?”. A change in one laboratory result does not automatically imply an overall benefit for all women.

Why there is no single “women-specific effect” of inositol

Studies were conducted in different age and metabolic groups. Participants included postmenopausal women, women undergoing the menopausal transition, and women with excess body weight and impaired carbohydrate metabolism.

The interventions also differed: myo-inositol alone, D-chiro-inositol alone, or inositol as part of a combination formula. Consequently, two studies with “inositol” in their titles may address entirely different questions.

Glucose and insulin are among the most frequently measured outcomes

Studies involving women often measured fasting glucose and fasting insulin. These values were also used to calculate HOMA-IR, an indirect measure used to assess insulin resistance.

For example, studies involving postmenopausal women with metabolic syndrome assessed glucose, insulin, and HOMA-IR alongside other measures. This enabled researchers to examine a broader metabolic profile rather than a single test result.

However, a detailed assessment of how much inositol changes insulin sensitivity requires a separate analysis. For I07, the important point is simply that these parameters were regularly used as study endpoints.

Lipid profile: cholesterol and triglycerides

Another common group of measures is blood lipids. Researchers measured triglycerides, total cholesterol, high-density lipoprotein cholesterol, and, in some studies, low-density lipoprotein cholesterol.

These tests help assess metabolic changes, but a change in a single lipid measure does not amount to a demonstrated reduction in cardiovascular risk. Such a conclusion requires other clinically meaningful outcomes.

Blood pressure was also assessed as a separate outcome

Studies of postmenopausal women measured systolic and diastolic blood pressure. Some analyzed these measures alongside HOMA-IR and the lipid profile.

This shows that researchers were interested not just in one biochemical pathway but in a wider set of metabolic parameters. At the same time, a blood pressure change in an individual study does not mean that inositol should be considered a treatment for high blood pressure.

Body weight, BMI, and waist circumference

Weight and anthropometric measures were also often included in study protocols. Researchers assessed body weight, body mass index, waist circumference, or waist-to-hip ratio.

An important example is a 12-month study involving 80 postmenopausal women. Alongside laboratory markers, BMI and waist circumference were measured, but no significant between-group advantage was found for these two measures.

This illustrates why improvements in laboratory measures should not be turned into claims about weight loss.

What was measured in postmenopausal women

Postmenopausal women form a distinct and prominent group in the literature on inositol. Studies focused primarily on metabolic health measures: glucose, insulin, HOMA-IR, triglycerides, cholesterol, blood pressure, and anthropometry.

Some studies included a much broader range of laboratory markers. For example, researchers evaluating a combination formula containing myo-inositol, cocoa polyphenols, and soy isoflavones measured adiponectin, visfatin, resistin, and bone-specific alkaline phosphatase.

However, this study design has an obvious limitation: when an intervention contains several active ingredients, the observed result cannot be attributed to myo-inositol alone.

Hormonal measures were studied too, but they are not a single category

The selection of hormonal tests differed substantially between studies. In women undergoing the menopausal transition, researchers assessed thyroid-stimulating hormone, free T3 and T4, and insulin. Other studies measured sex hormones, gonadotropins, prolactin, and other endocrine markers.

This is why the statement “inositol normalizes hormones” is too broad. It is always necessary to specify which hormone and which study are being discussed.

Menstrual cycle length may be a separate outcome

Some studies assessed not only laboratory tests but also menstrual cycle length. This represents a different type of outcome: an observable physiological characteristic rather than the concentration of a substance in the blood.

For example, a 2025 study using a high experimental dose of D-chiro-inositol assessed metabolic measures, sex hormones, and cycle length at the same time. The metabolic and hormonal changes went in different directions.

This study demonstrates why one favorable laboratory result cannot automatically be generalized to the entire hormonal or menstrual profile.

Adipokines and other specialized biomarkers

Some studies involving women went far beyond routine tests. They measured adiponectin, visfatin, and resistin — signaling molecules associated with adipose tissue and metabolic processes.

Some protocols also assessed bone-specific alkaline phosphatase, glycated hemoglobin, and other specialized measures. This broadens the picture but also increases the risk of mistakenly assuming that every biomarker change has the same practical significance.

What exactly was measured in studies involving women

Why a change in a laboratory measure is not the same as an overall benefit “for women”

When a study measures ten or more parameters at once, some may change while others do not. This is normal and does not in itself indicate a contradiction.

For example, in a 12-month study of postmenopausal women, changes in some metabolic measures were not accompanied by a significant advantage in BMI or waist circumference. In another study, a combination formula affected some biomarkers but not others.

The strength of a conclusion therefore depends on which outcome was primary, how large the study was, whether it included a control group, and whether the result can be attributed to inositol rather than other ingredients or accompanying lifestyle changes.

The form of inositol also matters

Not all studies used myo-inositol. In a 2025 study, 48 women with excess body weight and insulin resistance received high experimental doses of D-chiro-inositol alongside a calorie-restricted Mediterranean diet, or the diet alone.

Metabolic measures improved in both groups, whereas the authors reported unfavorable changes in some androgen-related measures and cycle length in the D-chiro-inositol group.

This example illustrates two points: the effects of the diet cannot be attributed to the supplement, and findings for one form of inositol should not automatically be applied to another.

How to read studies of inositol in women

• Who participated: age, menopausal status, body weight, and metabolic characteristics substantially affect the context.
• Which form was used: myo-inositol, D-chiro-inositol, or a combination intervention.
• What the primary outcome was: glucose, insulin, lipids, blood pressure, anthropometry, hormones, or another measure.
• Whether other active ingredients were included: if inositol was part of a combination formula, the effect cannot automatically be attributed to inositol alone.
• Whether laboratory and practical outcomes aligned: a change in a test result is not always accompanied by a change in body weight or another clinically important measure.

Frequently asked questions

What was measured most often in studies of inositol in women?
Common measures included glucose, insulin, HOMA-IR, lipid profile, blood pressure, body weight, and waist circumference. Some studies also included hormonal and other specialized measures.

Has inositol been studied in postmenopausal women?
Yes. Randomized studies in postmenopausal women have primarily assessed metabolic measures, lipids, blood pressure, and anthropometry.

Does an improvement in HOMA-IR mean that all other measures will improve too?
No. Different parameters can change independently. In some studies, laboratory measures changed without a significant advantage in BMI or waist circumference.

Were hormones studied?
Yes, but the panels of tests varied greatly between studies. Thyroid, sex, and other hormonal markers were assessed, so the general statement “affects hormones” is too imprecise.

Were body weight and waist circumference studied?
Yes. These measures were included in many protocols, but changes in laboratory markers were not always accompanied by significant anthropometric changes.

Can the results of a combination supplement be attributed to inositol alone?
No. If other active ingredients or a special diet were used alongside it, a separate comparison is needed to determine how much of the result is attributable specifically to inositol.

Do all forms of inositol produce the same results in women?
No. Myo-inositol and D-chiro-inositol have different physiological roles, and findings for one should not automatically be transferred to the other.

References

• Giordano D. et al. (2011). Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a prospective, randomized, placebo-controlled study. Menopause. PubMed
• D'Anna R. et al. (2012). One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. PubMed
• D'Anna R. et al. (2014). Effects of a new flavonoid and Myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: a randomized trial. PubMed
• D'Anna R. et al. (2017). Myo-inositol and melatonin in the menopausal transition. Gynecological Endocrinology. PubMed
• Santamaria A. et al. (2013). Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. PubMed
• Basciani S. et al. (2025). Unexpected effects of treating insulin-resistant obese women with high-dose D-chiro-inositol: opening Pandora's box. Frontiers in Endocrinology. PubMed
• Krysiak R. et al. (2023). Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women. PubMed

Food supplement. Not a medicinal product. Consult your healthcare professional before use.